Expression of HLA-DR and its enhancing molecules in muscle fibers in polymyositis

Muscle and Nerve

Volumn 23, Issue 3, 2000, Pages 385-392

  Inukai, Akira ^a   Kuru, Satosi ^a   Liang, Yideng ^a   Takano, Akemi ^a   Kobayashi, Yasushi ^a   Sakai, Motoko ^b   Doyu, Manabu ^a   Sobue, Gen ^a  

^a NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b National Hospital Organization   (Japan)

Author keywords

Antigen presentation; Class II transactivator; HLA DM; HLA DR; Invariant chain

Indexed keywords

HLA DR ANTIGEN;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; AUTOIMMUNE DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HLA SYSTEM; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPATHOGENESIS; MALE; MUSCLE BIOPSY; NUCLEOTIDE SEQUENCE; POLYMYOSITIS; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADULT; AGED; ANTIBODIES; BIOPSY; DNA PRIMERS; DNA, COMPLEMENTARY; FEMALE; GENE EXPRESSION; HLA-DR ANTIGENS; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPHOCYTES; MALE; MIDDLE AGED; MUSCLE FIBERS; MUSCLE, SKELETAL; POLYMYOSITIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 0033994982     PISSN: 0148639X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-4598(200003)23:3<385::AID-MUS10>3.0.CO;2-T     Document Type: Article

References (49)

1. Amigorena S, Drake JR, Webster P, Mellman I. Transient accumulation of new class II MHC molecules in a novel endocytic compartment in B lymphocytes. Nature 1994;369: 113-120.
2. Armstrong TD, Clements VK, Martin BK, Ting JP-Y, Ostrand-Rosenberg S. Major histocompatibility complex class II-transfected tumor cells present endogenous antigen and are potent inducers of tumor-specific immunity. Proc Natl Acad Sci USA 1997;94:6886-6891.
3. Bakke O, Dobberstein B. MHC class II-associated invariant chain contains a sorting signal for endosomal compartments. Cell 1990;63:707-716.
4. Bohan A, Peter JB. Polymyositis and dermatomyositis. N Engl J Med 1975;292:344-347; 403-407.
5. Bonnerot C, Marks MS, Cosson P, Robertoson EJ, Bikoff EK, German RN, Bonifacino S. Association with BiP and aggregation of class II MHC molecules synthesized in the absence of invariant chain. EMBO J 1994;13:934-944.
6. Bradley MB, Fernandez JM, Lingers G, Diaz-Barrientos T, Steimle V, Much B, O'Reilly R, Lee JS. Correction of defective expression in MHC class II deficiency (bare lymphocyte syndrome) cells by retroviral transduction of CIITA. J Immunol 1997;159:1086-1095.
7. Ceman S, Ruderdorf R, Long EO, DeMars R. MHC class II deletion mutant expresses normal levels of transgene encoded class II molecules that have abnormal conformation and impaired antigen presentation ability. J Immunol 1992; 149:754-761.
8. Chang CH, Flavell RA. Class II transactivator regulates the expression of multiple genes involved in antigen presentation. J Exp Med 1995;181:765-767.
9. Chang CH, Fontes JD, Peterlin M, Flavell RA. Class II transactivator (CIITA) is sufficient for the inducible expression of major histocompatibility complex class II genes. J Exp Med 1994;180:1367-1374.
10. Cresswell P. Assembly, transport and function of MHC class II molecules. Annu Rev Immunol 1994;12:259-293.
11. Denzin LK, Cresswell P. HLA-DM induces CLIP dissociation from MHC class II α β dimers and facilitates peptide loading. Cell 1995;82:15.5-165.
12. Devki N, Neil ER. TGF-β attenuates the class II transactivator and reveals an accessory pathway of IFN-γ action. J Immunol 1997;158:1095-1101.
13. Engel AG, Arahata K. Monoclonal antibody analysis of mononuclear cells in myopathies. II. Phenotypes of autoinvasive cells in polymyositis and inclusion body myositis. Ann Neurol 1984;16: 209-215.
14. Fling SP, Arp B, Pious D. HLA-DMA and -DMB genes are both required for MHC class II/peptide complex formation in antigen-presenting cells. Nature 1994;368:554-558.
15. Goebels N, Michaelis D, Wekerle H, Hohlfeld R. Human myoblasts as antigen-presenting cells. J Immunol 1992;149: 661-667.
16. Hohlfeld R, Engel AC. Induction of HLA-DR expression on human myoblasts with interferon-gamma. Am J Pathol 1990; 136:503-508.
17. Kalovidouris AE. The role of cytokines in polymyositis: interferon-γ induces class II and enhances class I major histocompatibility complex antigen expression on cultured human muscle cells. J Lab Clin Med 1992;120:244-251.
18. Karpati G, Pouliot Y, Carpenter S. Expression of immunoreactive major histocompatibility complex products in human skeleal muscles. Ann Neurol 1988;23:64-72.
19. Kelly AP, Monaco JJ, Cho S, Trowdale J. A new human HLA class II-related locus, DM. Nature 1991;353:571-573.
20. Klein C, Lisowska-Grospierre B, LeDeist F, A. Fischer A, Griscelli C. Major histocompalibility complex class II deficiency: clinical manifestations, imnumologic features, and outcome. J Pediatr 1993;123:921-928.
21. Lotteau V, Teyton L, Peleraux A, Nilsson T, Karlsson L, Schmid SL, Quaranta V, Peterson PA. Intracellular transport of class II MHC molecules directed by invariant chain. Nature 1990;348:600-605.
22. Lundberg I, Brengman JM, Engel AG. Analysis of cytokine expression in muscle in inflammatory myopathies, Duchenne dystrophy, and non-weak controls. J Neuroimmunol 1995;63: 9-16.
23. Mantegazza R, Hughes SM, Mitchell D, Travis M, Blau HM, Steinman L. Modulation of MHC class II antigen expression in human myoblasts after treatment with IFN-γ. Neurology 1991;41:1128-1132.
24. McDouall RM, Dunn MJ, Dubowitz V. Expression of class I and class II MHC antigens in neuromuscular diseases. J Neurol Sci 1989;89:213-226.
25. Mellins E, Smith L, Arp B, Cotner T, Celis E, Pious D. Defective processing and presentation of exogenous antigens in mutants with normal HLA class II genes. Nature 1990;343: 71-74.
26. Mizuochi T, Yee S-T, Kasai M, Kakiuchi T, Muno D, Kominami E. Both cathepsin B and cathepsin D are necessary for processing of ovalbumin as well as for degradation of class II MHC invariant chain. Immunol Lett 1994;43:189-193.
27. Monji T, McCormack AL, Yates III JR, Pious D. Invariant-cognate peptide exchange restores class II dimer stability in HLA-DM mutants. J Immunol 1994;153:4468-4477.
28. Morris P, Shaman J, Attaya M, Amaya M, Goodman S, Bergman C, Monaco JJ, Mellins E. An essential role for HLA-DM in antigen presentation by class II major histocompatibility molecules. Nature 1994;368:551-554.
29. Nuchtern JG, Biddison WE, Klausner RD. Class II MHC can use the endogenous pathway of antigen presentation. Nature 1990;343:74-76.
30. Nuovo GJ. PCR in situ hybridization: protocols and applications, 3rd edition. Philadelphia: Lippincott Raven; 1996. 271 p.
31. Olsson T, Henriksson KG, Klareskog L, Forsum U. HLA-DR expression. T lymphocyte phenotypes, OKM1 and OKT9 reactive cells in inflammatory myopathy. Muscle Nerve 1985;8: 419-425.
32. Otten LA, Steimle V, Bontron S, Mach B. Quantitative control of MHC: class II expression by the transactivator CIITA. Eur J Immunol 1998;28:473-478.
33. Patel VG, Shum-Siu A, Heniford BW, Wieman TJ, Hendler FJ. Detection of epidermal growth factor receptor mRNA in tissue sections from biopsy specimens using in situ polymerase chain reaction. Am J Pathol 1994;144:7-14.
34. Peters PJ, Neefjes JJ, Oorschot V, Ploegh HL, Geuze HJ. Segregation of MHC: class II molecules from MHC class I molecules in the Golgi complex for transport to lysosomal compartment. Nature 1991;349:669-676.
35. Peters PJ, Raposo G, Neefjes JJ, Oorschot V, Leijendekker RL, Geuze HJ, Ploegh HL. Major histocompatihility complex class II compartment in human B lymphoblastoid cells are distinct from early endosomes. J Exp Med 1995;182:325-334.
36. Riberdy JM, Avva RR, Geuze HJ, Cresswell P. Transport and intracellular distribution of MHC class II molecules and associated invariant chain in normal and antigen-processing mutant cell lines. J Cell Biol 1994;125:1225-1237.
37. Riberdy JM, Newcomb JR, Surman MJ, Barbosa JA, Creswell P. HLA-DR molecules from an antigen-processing mutant cell line are associated with invariant chain peptides. Nature 1992; 360:474-477.
38. Rieckmann P, Albrecht M, Kitze B, Weber T, Tumani H, Broocks A, Lüer W, Helwig A, Poser S. Tumor necrosis factor - a messenger RNA expression in patients with relapsing-remitting multiple sclerosis is associated with disease activity. Ann Neurol 1995;37:82-88.
39. Roche PA, Cresswell P. Invariant chain association with HLA-DR molecules inhibits immunogenic peptide binding. Nature 1990;345:615-618.
40. Rowe DJ, Isenberg DA, Mcdougall J, Beverley PCL. Characterization of polymyositis infiltrates using monoclonal antibodies to human leucocyte antigens. Clin Exp Immunol 1981; 45:290-298.
41. Sette A, Oman S, Kubo RT, Sakaguchi K, Appella E, Hunt DF, Davis TA, Michel H, Shabanowitz J, Rudersdorf R, Grey HM, DeMars R. Invariant chain peptides in most HLA-DR molecules of an antigen-processing mutant. Science 1992; 258:1801-1804.
42. Sloan VS, Cameron P, Porter G, Gammon M, Amaya M, Mellins E, Zaller DM. Mediation by HLA-DM of dissociation of peptides from HLA-DR. Nature 1995;375:802-806.
43. Steimle V, Oten LA, Zufferey M, Mach B. Complementation cloning of an MHC class II transactivator mutated in hereditary MHC class II deficiency (or bare lymphocyte syndrome). Cell 1993;75:135-146.
44. Steimle V, Siegrist CA, Mottet A, Lisowska-Grospierre B, Mach B. Regulation of MHC class II expression by interferon-γ mediated by the transactivator gene CIITA. Science 1994;265: 106-109.
45. Sugimoto T, Tsukamoto F, Fujita M, Takai S. Ki-ras and c-myc oncogene expression measured by coamplification polymerase chain reaction. Biochem Biophys Res Commun 1994;201: 574-580.
46. Viville S, Neefjes J, Lotteau V, Dierich A, Lemeur M, Ploegh H, Benoist C, Mathis D. Mice lacking the MHC class II-associated invariant chain. Cell 1993;72:635-648.
47. Whitaker JN. Inflammatory myopathy: a review of etiologic and pathogenic factors. Muscle Nerve 1982;5:573-592.
48. Yamamura M, Uyemura K, Deans RJ, Weinberg K, Rea TH, Bloom BR, Modlin RL. Defining protective responses to pathogens: cytokine profiles in leprosy lesions. Science 1991; 254:277-279.
49. Zuk JA, Fletcher A. Skeletal muscle expression of class II histocompatibility antigens (HLA-DR) in polymyositis and other muscle disorders with an inflammatory infiltrate. J Clin Pathol 1988;41:410-414.